08:00 | Registration |
| Advances in Protein and Antibody Arrays |
| |
09:00 | | Keynote Presentation Protein Microarray Technologies - Analysis of Signaling Networks in Human Tumours Markus Templin, Head, University of Tuebingen, Germany
Complex data sets generated from limiting sample material allow the identification of differences in activation of signaling networks directly on the protein level. Protein microarray analysis during anti- cancer drug development demonstrate the power of this technology. |
|
10:00 | Application of ChIP-on-chip Technology for Elucidating the Role of The Transcriptional Regulator AtrA in Streptomyces Coelicolor Georgios Efthimiou, Postdoctoral Researcher, Metropolitan College, National and Kapodistrian University of Athens , Greece
A ChIP-on-chip method identified the binding loci of the transcription factor AtrA in the genome of Streptomyces coelicolor. Many genes were found to be regulated by AtrA, involved in processes such as primary metabolism, cell division and antibiotic production. |
10:30 | Coffee Break and Networking in the Exhibition Hall |
11:15 | Identification of a Protein Biomarker Signature Using Reverse Phase Protein Arrays (RPPA) for Risk Classification of Estrogen Receptor-Positive Breast Cancer Ulrike Korf, Senior Scientist/Group Leader, German Cancer Research Center, Germany
Using reverse phase protein arrays (RPPA) a protein signature was identified that can distinguish between high and low risk luminal breast cancer. |
11:45 | Antibody-centric Profiling of Plasma Proteins in Disease Biobanks Jochen Schwenk, Director- Plasma Profiling Facility, KTH Royal Institute of Technology, Sweden
The presentation will be about discovery projects for which antibodies from the Human Protein Atlas project and suspension bead array technology are used to protein profile serum and plasma. |
12:15 | Lunch and Networking in Exhibition Hall |
13:30 | Poster Viewing Session |
14:15 | Next Generation Arrays - Technology and Possibilities in Biomedicine Carl Borrebaeck, Professor and Deputy Vice Chancellor, Lund University, Sweden
The specificities in antibody microarrays introduce a bias regarding which compartment to interrogate. We now describe the development of the next generation arrays, where discovery of previously unknown protein biomarkers can be achieved, using so called context independent motif-specific antibodies. |
14:45 | Polysaccharide Microarrays with a CMOS Based Signal Detection Thomas Brandstetter, Group Leader, University of Freiburg, Germany
A simple procedure to create polysaccharide microarrays is presented, which can be used to analyze antibodies using an integrated, CMOS-based electric signal readout process including either chemiluminescence or fluorescence based detection. |
15:15 | Coffee Break and Networking in the Exhibition Hall |
16:00 | Fast-Tracking Molecular Diagnostics in Oncology via Antibody-Based Proteomics and Digital Pathology William Gallaghr, Chief Scientific Officer/Professor, OncoMark Limited/University College Dublin, Ireland
This presentation will cover the utility of antibody-based profiling using tissue microarrays and associated digital pathology approaches to expedite the transition from biomarker discovery to validation in oncology. Case studies covering a range of cancer and biomarker types will be outlined. |
| Molecular Diagnostics |
| |
16:30 | Molecular Portraits of Systemic Lupus Erythematosus - unlocking Biomarker Discovery Using Antibody Micro- and Nanoarrays Christer Wingren, Associate Professor And Lecturer, Lund University, Sweden
We have designed antibody micro- and nanoarrays for unlocking biomarker discovery. Using system lupus erythematosus as a showcase, we illustrate the potential of the technology platform for deciphering molecular portraits of the disease, paving the way for improved diagnosis and prognosis. |
17:00 | A Dual Label/Label Free, Highly Sensitive Protein Microarray Platform for Molecular Diagnostics Marina Cretich, Researcher, National Research Council, Italy
In this presentation, a fluorescence microarray platform endowed with high sensitivity, coupled to label-free imaging for accurate quantification of immobilized probes is shown. Succesful examples of clinical relevance in the area of food allergy, inflammation, sepsis and Alzheimer's disease will be presented. |
17:45 | Round Table Discussions in Exhibition Hall |